Harvey D. White, MD, DSc, FACC
Cardiologist & Director of the Green Lane Cardiovascular Research Unit
Auckland City Hospital

Printed as of 11/22/2026

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
CSL Behring LLC	Other - *Research grant to the Institution and financial fees as Steering Committee member of the AEGIS-II study.*	Significant (>= $5,000)	*General Cardiology*
DalCor Pharma UK Inc.	Other - *Research grant to the Institution and financial fees as Steering Committee member for Dal-GenE Study*	Significant (>= $5,000)	*General Cardiology*
Janssen Pharmaceuticals, Inc	Other - *Fees for serving on the Steering Committee for the Librexia AF and ACS studies*	Significant (>= $5,000)	*General Cardiology*
Merck Sharp & Dohme (New Zealand) Ltd	Other - *Research grant to the institution and fees for serving on the Steering Committee for the MK0616 study trial*	Significant (>= $5,000)	*General Cardiology*
National Institutes of Health (USA)	Research/Research Grants *‡ Resaerch grants for the ISCHEMIA and MINT Studies*	Significant (>= $5,000)	*General Cardiology*

Additional Personal Commercial Disclosures for Education Activities (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Regent	Research/Research Grants *‡ HEART-FID*	Significant (>= $5,000)	*General Cardiology*
VEVRE	Consultant Fees/Honoraria	Modest (< $5,000)	*General Cardiology*

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
CSL Behring	Other - *Advisory Board*	Modest (< $5,000)	*General Cardiology*
NHMRC Clinical Trials Centre, the University of Sydney *† Chair of the DSMB for the EVIDENCE Study.*	Data Safety Monitoring Board	None ($0)	*General Cardiology*
SAHMRI	Other - *Accommodation support paid to self for attendance at the Clinical trial forum 2023*	Modest (< $5,000)	*General Cardiology*
VEVRE	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/29/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/29/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/29/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/29/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.